Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

8.680 -0.260 (-2.91%)
Streaming Delayed Price Updated: 11:03 AM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,114,129
Open 9.000
Bid (Size) 8.680 (3)
Ask (Size) 8.690 (8)
Prev. Close 8.940
Today's Range 8.210 - 9.450
52wk Range 2.685 - 17.00
Shares Outstanding 46,772,263
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Replimune Stock Was Soaring Today
An investigational treatment, used in combination with another cancer medication, took an important step forward after several setbacks. 
Via The Motley Fool
These stocks are moving in today's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill

Performance

YTD
-30.9%
-30.9%
1 Month
+165.4%
+165.4%
3 Month
-29.6%
-29.6%
6 Month
-1.0%
-1.0%
1 Year
-23.5%
-23.5%

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
These stocks are the most active in today's session
Via Chartmill
What Is Driving Replimune Stock’s 98% Surge Today?
Via Stocktwits
Top movers analysis in the middle of the day on 2025-10-20: top gainers and losers in today's session.
Via Chartmill
Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today
Via Benzinga
Gapping stocks in Monday's session
Via Chartmill
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Artificial Intelligence
Dow Jumps Over 200 Points; Cleveland-Cliffs Shares Jump After Q3 Results
Via Benzinga
Topics Stocks
These stocks are moving in today's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
From Replimune, Inc.
Via GlobeNewswire
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
From Replimune, Inc.
Via GlobeNewswire
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
From Faruqi & Faruqi, LLP
Via Business Wire
REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Replimune Group, Inc. Investors to Contact the Firm Regarding Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire
Levi & Korsinsky Notifies Shareholders of Replimune Group, Inc. (REPL) of a Class Action Lawsuit and an Upcoming Deadline
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Notifies Shareholders of Replimune Group, Inc. (REPL) of a Class Action Lawsuit and an Upcoming Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
From Faruqi & Faruqi LLP
Via GlobeNewswire
REPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPL
From The Rosen Law Firm, P.A.
Via Business Wire
Why Replimune Stock Was Tumbling Again Today
Via The Motley Fool
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22nd
From Bragar Eagel & Squire
Via GlobeNewswire
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 22, 2025 - REPL
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 22, 2025 - REPL
Via TheNewswire.com
Topics Fraud Lawsuit

Frequently Asked Questions

Is Replimune Group, Inc. - Common Stock publicly traded?
Yes, Replimune Group, Inc. - Common Stock is publicly traded.
What exchange does Replimune Group, Inc. - Common Stock trade on?
Replimune Group, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Replimune Group, Inc. - Common Stock?
The ticker symbol for Replimune Group, Inc. - Common Stock is REPL on the Nasdaq Stock Market
What is the current price of Replimune Group, Inc. - Common Stock?
The current price of Replimune Group, Inc. - Common Stock is 8.680
When was Replimune Group, Inc. - Common Stock last traded?
The last trade of Replimune Group, Inc. - Common Stock was at 10/21/25 11:03 AM ET
What is the market capitalization of Replimune Group, Inc. - Common Stock?
The market capitalization of Replimune Group, Inc. - Common Stock is 405.98M
How many shares of Replimune Group, Inc. - Common Stock are outstanding?
Replimune Group, Inc. - Common Stock has 406M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.